ThromboGenics announces 2013 growth thanks to Jetrea sales

18 March 2014

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has released its financial results for the full year 2013, showing that its lead product has helped boost growth.

The company recorded revenues of 112.8 million euros ($156.8 million) in 2013, compared with 75.1 million euros in 2012.Gross profit in 2013 was 106.4 million euros compared to 72.0 million euros in 2012. The majority of revenue was the 90 million euros in upfront payment received from Alcon, the ophthalmic unit of Swiss drug major Novartis (NOVN: VX), as part of the strategic agreement to commercialize Jetrea (ocriplasmin) outside of the USA in March 2012.

Product sales

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK